gwen a melincoff executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of adolor corporation snapshotpeople  overviewboard memberscommittees executive profile gwen a melincoff vice president of business development adolor corporationagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background ms gwen a melincoff serves as managing director at gemini advisors llc ms melincoff is an advisor to phase  ventures and verge genomics she has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned public and private company boards venture financing business development licensing mergers and acquisitions research operations marketing product management and project management she served as a  senior vice president of shire strategic investment group from august  to september  she served as vice president of business development at btg international inc a uk specialist healthcare company from september  to december  she served as senior vice president of business development at shire pharmaceuticals additionally from  to  she led the strategic investment group sig she served as senior vice president of business development at shire plc she has been involved in numerous licenses product divestments copromotion and collaboration agreements and mergers and acquisitions she was responsible for the collaboration with new river pharmaceuticals she served as vice president of business development at adolor corporation she worked for eastman kodak for over ten years including eastman pharmaceuticals from october  to january  she served as director of business development at nanosystems a subsidiary of eastman kodak and after october  a division of elan corporation plc where she was responsible for identifying and implementing the marketing and business development strategies she has been a director at photocure asa since april   she has been an independent director of kamada ltd since february   she served as a director of tobira therapeutics inc from june   to november   she served as a board memberboard observer at dbv technologies am pharma armagen technologies promethera biosciencs naurex inc acquired by allergan and enterome she served as a director of dbv technologies sa she held managerial and business development position at various pharmaceutical companies such as adolor corporation she is a certified licensing professional she was named a top women in biotech  by fierce biotech as well as being named to the powerlist  of corporate venture capitalist in  and  ms melincoff received a bs in biology from george washington university and a ms in management  health care administration from penn state universityread full background corporate headquarters  pennsylvania driveexton pennsylvania united statesphone fax  board members memberships presentdirectorphotocure asapresentindependent directorkamada ltd education bs the george washington universityms pennsylvania state university other affiliations shire plcphotocure asathe george washington universitypennsylvania state universitydbv technologies sakamada ltdtobira therapeutics incshire strategic investment group annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact adolor corporation please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors globenewswire feb    am est ness ziona israel feb   globe newswire  kamada ltd nasdaqkmda tasekmda a plasmaderived protein therapeutics company focused on orphan indications announced today the appointment of gwen a melincoff to the companys board of directors  ms melincoff has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned venture financing business development licensing mergers and acquisitions research operations marketing product management project management and public and private company boards ms melincoff is currently an advisor to phase  ventures an accelerator startup program and verge genomics a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases from august  to september  she served as vice president of business development at btg international inc a ukbased specialist healthcare company  from  to  ms melincoff was senior vice president of business development at shire pharmaceuticals additionally from  to  she led the companys strategic investment group sig prior to joining shire ms melincoff held managerial and business development positions at various pharmaceutical companies including adolor corporation  ms melincoff has served as a board memberboard observer at tobira therapeutics acquired by allergan dbv technologies am pharma armagen technologies promethera biosciences naurex inc acquired by allergan and enterome we are pleased to welcome ms melincoff to our board of directors said leon recanati kamadas chairman of the board  gwen has vast operational experience and expertise across the biotechnology and pharmaceutical industries  her year career across multiple corporate functions including business development licensing research operations marketing product management and project management will be significant to us as we continue to drive growth across our commercial product portfolio and further develop our robust latestage pipeline  with the addition of ms melincoff and of dr michael berelowitz who joined our board of directors in  after serving as senior vice president and head of clinical development and medical affairs in the specialty care business unit at pfizer we have strengthened our board with senior usbased pharma executives who bring tremendous value to the company if you liked this article you might like biotech movers shire falls on stem cell program transfer calithera synergy up on fda approvals plus more from the biotechnology world on wednesday june  william mcconnell jun    am edt  biotechs set to provide a shot in the arm each company has approaching catalysts bret jensen sep    am edt  biotechs set to provide a shot in the arm each company has approaching catalysts bret jensen sep    am edt  stocks pushing the drugs industry lower thestreet highlights  stocks pushing the drugs industry lower today thestreet wire aug    pm edt trending facebook could plunge by  or more in a few hours corning takes damaging hit on earnings  heres where investors can buy advanced micro devices could explode another  within hours chart when will google and microsoft finally break out cloud sales as amazon does jim cramer reveals what to watch in southwest airlines dow chemical and starbucks earnings advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors  pt community skip to main content pt community registersign in search form search home news ptcurrent issue past issues masthead digital edition subscribe pt tv authors about contact us   ingrezza® valbenazine tablets‎ zurampic® lesinurad tabletsplease click for full prescribing information including boxed warning you are herehome kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors ness ziona israel feb   globe newswire  kamada ltd nasdaqkmda tasekmda a plasmaderived protein therapeutics company focused on orphan indications announced today the appointment of gwen a melincoff to the company’s board of directors  ms melincoff has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned venture financing business development licensing mergers and acquisitions research operations marketing product management project management and public and private company boards ms melincoff is currently an advisor to phase  ventures an accelerator startup program and verge genomics a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases from august  to september  she served as vice president of business development at btg international inc a ukbased specialist healthcare company  from  to  ms melincoff was senior vice president of business development at shire pharmaceuticals additionally from  to  she led the company’s strategic investment group sig prior to joining shire ms melincoff held managerial and business development positions at various pharmaceutical companies including adolor corporation  ms melincoff has served as a board memberboard observer at tobira therapeutics acquired by allergan dbv technologies am pharma armagen technologies promethera biosciences naurex inc acquired by allergan and enterome “we are pleased to welcome ms melincoff to our board of directors” said leon recanati kamada’s chairman of the board  “gwen has vast operational experience and expertise across the biotechnology and pharmaceutical industries  her year career across multiple corporate functions including business development licensing research operations marketing product management and project management will be significant to us as we continue to drive growth across our commercial product portfolio and further develop our robust latestage pipeline  with the addition of ms melincoff and of dr michael berelowitz who joined our board of directors in  after serving as senior vice president and head of clinical development and medical affairs in the specialty care business unit at pfizer we have strengthened our board with senior usbased pharma executives who bring tremendous value to the company” ms melincoff was named one of fierce biotech’s “top women in biotech ” as well as being named to the powerlist  of corporate venture capital in  and   she has a bs in biology a master’s of science in management and has obtained the designation of the certified licensing professional clp™ about kamadakamada ltd is focused on plasmaderived protein therapeutics for orphan indications and has a commercial product portfolio and a robust latestage product pipeline the company uses its proprietary platform technology and knowhow for the extraction and purification of proteins from human plasma to produce alpha antitrypsin aat in a highlypurified liquid form as well as other plasmaderived immune globulins  aat is a protein derived from human plasma with known and newlydiscovered therapeutic roles given its immunomodulatory antiinflammatory tissueprotective and antimicrobial properties the company’s flagship product is glassia® the first and only liquid readytouse intravenous plasmaderived aat product approved by the us food and drug administration kamada markets glassia® in the us through a strategic partnership with baxalta now part of shire plc and in other counties through local distributors  in addition to glassia® kamada has a product line of seven other pharmaceutical products administered by injection or infusion that are marketed through distributors in more than  countries including israel russia brazil india and other countries in latin america and asia kamada has five latestage plasmaderived protein products in development including an inhaled formulation of aat for the treatment of aat deficiency for which a maa was submitted to the ema after completing a pivotal phase  clinical trials in europe  kamada has also completed its phase  clinical trials in the us for the treatment of aat deficiency with inhaled aat in addition kamadas intravenous aat is in development for other indications such as type diabetes gvhd and prevention of lung transplant rejection kamada also leverages its expertise and presence in the plasmaderived protein therapeutics market by distributing more than  complementary products in israel that are manufactured by third parties cautionary note regarding forwardlooking statements this release includes forwardlooking statements within the meaning of section a of the us securities act of  as amended section e of the us securities exchange act of  as amended and the safe harbor provisions of the us private securities litigation reform act of   forwardlooking statements are statements that are not historical facts such as statements regarding assumptions and results related to financial results forecast commercial results timing and results of clinical trials and ema and us fda submissions and authorizations  forwardlooking statements are based on kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks uncertainties and assumptions  actual results and the timing of events could differ materially from those anticipated in these forwardlooking statements as a result of several factors including but not limited to unexpected results of clinical trials delays or denial in the us fda or the ema approval process additional competition in the aatd market or further regulatory delays  the forwardlooking statements made herein speak only as of the date of this announcement and kamada undertakes no obligation to update publicly such forwardlooking statements to reflect subsequent events or circumstances except as otherwise required by law contact contacts gil efron chief financial officer irkamadacom bob yedid lifesci advisors llc  boblifesciadvisorscomwednesday february     stay in touch newsletters available pt and drug management daily news pt table of contents monthly contact us editorial j stephen mciver editoradvertising maureen dwyer liberti vice president group publisherproduction dawn flook director of production servicescirculation jackie ott circulation managerwebmaster webmaster industry announcements affimed presents data on firstinclass bcmatargeting immune cell engager afm at asco annual meeting  share buyback week  novartis drug tasigna receives eu approval for inclusion of treatmentfree remission tfr data in product label basilea announces presentation of interim phase a clinical data with anticancer drug candidate bal at asco meeting targovax presents further positive clinical data from tg phase iii trial at  asco annual meeting addex annual general meeting scheduled for  june  valneva to present at jefferies  global healthcare conference in new york targovax announces formal agenda for  capital markets updates in oslo and london lundbeck obtains rights to breakthrough research in alzheimer’s disease veloxis pharmaceuticals as announces agreement with chiesi farmaceutici spa to commercialize envarsus xr in china more from globe newswire current issue of pt july  user login username  password  create new account request new password kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors  kamada english    עברית about us about us overview company profile directors and management our capabilities social responsibility become a partner careers at kamada products product catalog lung disease vaccines haemophilia immunoglobulins critical care diagnostics clinical pipeline pipeline overview alpha  deficiency gvhd diabetes type  lung transplantation rabies immunoglobulin alpha alpha overview ‪learn about alpha‬‬ testing for alpha alpha in kamada investors investors overview news  events financial reports stock quotes investors kit analyst coverage corporate governance ir contact  faq media news events  webcasts kamada milestones contact us about us about us overview company profile directors and management our capabilities social responsibility become a partner careers at kamada products product catalog lung disease vaccines haemophilia immunoglobulins critical care diagnostics clinical pipeline pipeline overview alpha  deficiency gvhd diabetes type  lung transplantation rabies immunoglobulin alpha alpha overview ‪learn about alpha‬‬ testing for alpha alpha in kamada investors investors overview news  events financial reports stock quotes investors kit analyst coverage corporate governance ir contact  faq media news events  webcasts kamada milestones contact us join our mailing list kamada » media » news news kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors feb   ness ziona israel – february   – kamada ltd nasdaq and tase kmda a plasmaderived protein therapeutics company focused on orphan indications announced today the appointment of gwen a melincoff to the company’s board of directors ms melincoff has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned venture financing business development licensing mergers and acquisitions research operations marketing product management project management and public and private company boards ms melincoff is currently an advisor to phase  ventures an accelerator startup program and verge genomics a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases from august  to september  she served as vice president of business development at btg international inc a ukbased specialist healthcare company from  to  ms melincoff was senior vice president of business development at shire pharmaceuticals additionally from  to  she led the company’s strategic investment group sig prior to joining shire ms melincoff held managerial and business development positions at various pharmaceutical companies including adolor corporation ms melincoff has served as a board memberboard observer at tobira therapeutics acquired by allergan dbv technologies am pharma armagen technologies promethera biosciences naurex inc acquired by allergan and enterome “we are pleased to welcome ms melincoff to our board of directors” said leon recanati kamada’s chairman of the board “gwen has vast operational experience and expertise across the biotechnology and pharmaceutical industries her year career across multiple corporate functions including business development licensing research operations marketing product management and project management will be significant to us as we continue to drive growth across our commercial product portfolio and further develop our robust latestage pipeline with the addition of ms melincoff and of dr michael berelowitz who joined our board of directors in  after serving as senior vice president and head of clinical development and medical affairs in the specialty care business unit at pfizer we have strengthened our board with senior usbased pharma executives who bring tremendous value to the company” ms melincoff was named one of fierce biotech’s “top women in biotech ” as well as being named to the powerlist  of corporate venture capital in  and  she has a bs in biology a master’s of science in management and has obtained the designation of the certified licensing professional clp™ about kamada kamada ltd is focused on plasmaderived protein therapeutics for orphan indications and has a commercial product portfolio and a robust latestage product pipeline the company uses its proprietary platform technology and knowhow for the extraction and purification of proteins from human plasma to produce alpha antitrypsin aat in a highlypurified liquid form as well as other plasmaderived immune globulins aat is a protein derived from human plasma with known and newlydiscovered therapeutic roles given its immunomodulatory antiinflammatory tissueprotective and antimicrobial properties the company’s flagship product is glassia® the first and only liquid readytouse intravenous plasmaderived aat product approved by the us food and drug administration kamada markets glassia® in the us through a strategic partnership with baxalta now part of shire plc and in other counties through local distributors in addition to glassia® kamada has a product line of seven other pharmaceutical products administered by injection or infusion that are marketed through distributors in more than  countries including israel russia brazil india and other countries in latin america and asia kamada has five latestage plasmaderived protein products in development including an inhaled formulation of aat for the treatment of aat deficiency for which a maa was submitted to the ema after completing a pivotal phase  clinical trials in europe kamada has also completed its phase  clinical trials in the us for the treatment of aat deficiency with inhaled aat in addition kamadas intravenous aat is in development for other indications such as type diabetes gvhd and prevention of lung transplant rejection kamada also leverages its expertise and presence in the plasmaderived protein therapeutics market by distributing more than  complementary products in israel that are manufactured by third parties cautionary note regarding forwardlooking statements this release includes forwardlooking statements within the meaning of section a of the us securities act of  as amended section e of the us securities exchange act of  as amended and the safe harbor provisions of the us private securities litigation reform act of  forwardlooking statements are statements that are not historical facts such as statements regarding assumptions and results related to financial results forecast commercial results timing and results of clinical trials and ema and us fda submissions and authorizations forwardlooking statements are based on kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks uncertainties and assumptions actual results and the timing of events could differ materially from those anticipated in these forwardlooking statements as a result of several factors including but not limited to unexpected results of clinical trials delays or denial in the us fda or the ema approval process additional competition in the aatd market or further regulatory delays the forwardlooking statements made herein speak only as of the date of this announcement and kamada undertakes no obligation to update publicly such forwardlooking statements to reflect subsequent events or circumstances except as otherwise required by law contacts gil efron chief financial officer irkamadacom bob yedid lifesci advisors llc  boblifesciadvisorscom news events  webcasts kamada milestones join our mailing list sign up to receive email updates from kamada latest news kamada submits proposed phase  protocol to fda for inhaled alphaantitrypsin for treatment of alpha antitrypsin deficiency disease jul      terms of use  privacy policy  sitemap   kamada  high quality pharmaceuticals  designed by titan brandwise gwen a melincoff  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in gwen a melincoff former board member at tobira therapeutics inc view full profile are you gwen a melincoff claim your profile   sign up for equilar atlas and view gwen a melincoffs full profile with equilar atlas you can identify corporate executives in gwen a melincoffs network and community follow changes in gwen a melincoffs employment and moneyinmotion connect with gwen a melincoff through your network of contacts gwen a melincoffs executive work history past to view gwen a melincoffs complete executive work history sign up now age      gwen a melincoffs biography ms melincoff has served as a member of tobiras board of directors since june  since august  ms melincoff has served as vice president business development at btg international inc a healthcare company from september  to december  ms melincoff was senior vice president of business development at pharmaceutical company shire plc and headed the shire strategic investment group the venture capital arm of shire plc prior to joining shire ms melincoff was vice president of business development at adolor corporation a biopharmaceutical company focused on the development of pain management products earlier in her care  read more ms melincoff has served as a member of tobiras board of directors since june  since august  ms melincoff has served as vice president business development at btg international inc a healthcare company from september  to december  ms melincoff was senior vice president of business development at pharmaceutical company shire plc and headed the shire strategic investment group the venture capital arm of shire plc prior to joining shire ms melincoff was vice president of business development at adolor corporation a biopharmaceutical company focused on the development of pain management products earlier in her career ms melincoff worked for eastman kodak company for over ten years in a number of their health care companies ms melincoff received a bs in biology from the george washington university and an ms in management and health care administration from pennsylvania state university source tobira therapeutics inc on    sign up for equilar atlas and view gwen a melincoffs full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like gwen a melincoff more specifically youll be able to identify corporate executives in gwen a melincoffs network and community follow changes in gwen a melincoffs employment and moneyinmotion connect with gwen a melincoff through your network of conections view full profile   search for over  executive profiles bio example gwen a melincoff gwen a melincoffs connections  sign up now to view gwen a melincoffs  connections » carol l brosgart former board member tobira therapeutics inc dennis g podlesak board member syndax pharmaceuticals inc eric lefebvre chief medical officer tobira therapeutics inc eckard weber chairman of the board ocera therapeutics inc patrick j heron former board member tobira therapeutics inc christopher peetz chief financial officer and head corporate development tobira therapeutics inc laurent fischer chief executive officer tobira therapeutics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla david j oconnor president and ceo the madison square garden company carl g annessa evp and coo hornbeck offshore services inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   home site map about us media kit contact us help register now why register login  the leading web portal for pharmacy resources news education and careers july   news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry pharmacy careers pharmacist pharmacy technician pharmacy job board job placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug database fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy schools pharmacy technician training business advertising information  media kit consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply dispensing systems tablet  capsule counters wholesalers  distributors more pharmacy choice  pharmaceutical news  kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors  july   pharmacy news article    kamada announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors ness ziona israel feb   globe newswire kamada ltd nasdaqkmda tasekmda a plasmaderived protein therapeutics company focused on orphan indicationsannounced today the appointment of gwen a melincoff to the companys board of directors ms melincoff has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned venture financing business development licensing mergers and acquisitions research operations marketing product management project management and public and private company boards ms melincoff is currently an advisor to phase  ventures an accelerator startup program and verge genomics a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases from august  to september  she served as vice president of business development at btg international inc a ukbased specialist healthcare company from  to  ms melincoff was senior vice president of business development at shire pharmaceuticals additionally from  to  she led the companys strategic investment group sig prior to joining shire ms melincoff held managerial and business development positions at various pharmaceutical companies including adolor corporation ms melincoff has served as a board memberboard observer at tobira therapeutics acquired by allergan dbv technologies am pharma armagen technologies promethera biosciences naurex inc acquired by allergan and enterome we are pleased to welcome ms melincoff to our board of directors said leon recanati kamadas chairman of the board gwen has vast operational experience and expertise across the biotechnology and pharmaceutical industries her year career across multiple corporate functions including business development licensing research operations marketing product management and project management will be significant to us as we continue to drive growth across our commercial product portfolio and further develop our robust latestage pipeline with the addition of ms melincoff and of dr michael berelowitz who joined our board of directors in  after serving as senior vice president and head of clinical development and medical affairs in the specialty care business unit at pfizer we have strengthened our board with senior usbased pharma executives who bring tremendous value to the company ms melincoff was named one of fierce biotechs top women in biotech  as well as being named to the powerlist  of corporate venture capital in  and  she has a bs in biology a masters of science in management and has obtained the designation of the certified licensing professional clp about kamadakamada ltd is focused on plasmaderived protein therapeutics for orphan indications and has a commercial product portfolio and a robust latestage product pipeline the company uses its proprietary platform technology and knowhow for the extraction and purification of proteins from human plasma to produce alpha antitrypsin aat in a highlypurified liquid form as well as other plasmaderived immune globulins aat is a protein derived from human plasma with known and newlydiscovered therapeutic roles given its immunomodulatory antiinflammatory tissueprotective and antimicrobial properties the companys flagship product is glassia the first and only liquid readytouse intravenous plasmaderived aat product approved by the us food and drug administration kamada markets glassia in the us through a strategic partnership with baxalta now part of shire plc and in other counties through local distributors in addition to glassia kamada has a product line of seven other pharmaceutical products administered by injection or infusion that are marketed through distributors in more than  countries including israel russia brazil india and other countries in latin america and asia kamada has five latestage plasmaderived protein products in development including an inhaled formulation of aat for the treatment of aat deficiency for which a maa was submitted to the ema after completing a pivotal phase  clinical trials in europe kamada has also completed its phase  clinical trials in the us for the treatment of aat deficiency with inhaled aat in addition kamadas intravenous aat is in development for other indications such as type diabetes gvhd and prevention of lung transplant rejection kamada also leverages its expertise and presence in the plasmaderived protein therapeutics market by distributing more than  complementary products in israel that are manufactured by third parties cautionary note regarding forwardlooking statements this release includes forwardlooking statements within the meaning of section a of the us securities act of  as amended section e of the us securities exchange act of  as amended and the safe harbor provisions of the us private securities litigation reform act of  forwardlooking statements are statements that are not historical facts such as statements regarding assumptions and results related to financial results forecast commercial results timing and results of clinical trials and ema and us fda submissions and authorizations forwardlooking statements are based on kamadas current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks uncertainties and assumptions actual results and the timing of events could differ materially from those anticipated in these forwardlooking statements as a result of several factors including but not limited to unexpected results of clinical trials delays or denial in the us fda or the ema approval process additional competition in the aatd market or further regulatory delays the forwardlooking statements made herein speak only as of the date of this announcement and kamada undertakes no obligation to update publicly such forwardlooking statements to reflect subsequent events or circumstances except as otherwise required by law contacts gil efron chief financial officer irkamadacom bob yedid lifesci advisors llc  boblifesciadvisorscom source kamada ltd  globenewswire inc pharmacy news index   drug delivery systems   drugstores   fda final approvals   front page healthcare news   generic drugs   hospital industry   internet pharmacy   it in healthcare   medicare  medicaid   overthecounter drugs   pharm industry trends and policy   pharmaceutical development   pharmaceutical industry live online ce jul  management of schizophrenia  acute agitation jul  on the move a comprehensive review of osteoarthritis gout  rheumatoid arthritis jul  obesity management overview of pharmacotherapy aug  treatment of depression and anxiety in older adults aug  adverse drug events risk reduction  documentation click for entire webinar calendar special announcement free membership enjoy drug search industry newsletters and more nursing jobs are you a nurse looking for a job check out the nursing job source your number one choice for nursing jobs websites » rxcareercentercom • rxschoolcom • clubstaffingcom • nursingjobsourcecom • rncom news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry careers pharmacist pharmacy technician pharmacy job board jobs placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug databases fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy ce pharmacy schools pharmacy tech training business advertising information consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply   dispensing systems tablet  capsule counters wholesalers  distributors more most popular pharmacy jobs continuing education fda resources drug information pharmacy news disease states pharm tech training copyright   pharmacy choice  all rights reserved terms and conditions  privacy statement  kamada ltd announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       kamada ltd kmda announces appointment of biopharmaceutical industry veteran gwen melincoff to its board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs ness ziona israel feb   globe newswire  kamada ltd nasdaqkmda tasekmda a plasmaderived protein therapeutics company focused on orphan indications announced today the appointment of gwen a melincoff to the company’s board of directors  ms melincoff has over  years of leadership experience in the biotechnology and pharmaceutical industries her experience has spanned venture financing business development licensing mergers and acquisitions research operations marketing product management project management and public and private company boards ms melincoff is currently an advisor to phase  ventures an accelerator startup program and verge genomics a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases from august  to september  she served as vice president of business development at btg international inc a ukbased specialist healthcare company  from  to  ms melincoff was senior vice president of business development at shire pharmaceuticals additionally from  to  she led the company’s strategic investment group sig prior to joining shire ms melincoff held managerial and business development positions at various pharmaceutical companies including adolor corporation  ms melincoff has served as a board memberboard observer at tobira therapeutics acquired by allergan dbv technologies am pharma armagen technologies promethera biosciences naurex inc acquired by allergan and enterome “we are pleased to welcome ms melincoff to our board of directors” said leon recanati kamada’s chairman of the board  “gwen has vast operational experience and expertise across the biotechnology and pharmaceutical industries  her year career across multiple corporate functions including business development licensing research operations marketing product management and project management will be significant to us as we continue to drive growth across our commercial product portfolio and further develop our robust latestage pipeline  with the addition of ms melincoff and of dr michael berelowitz who joined our board of directors in  after serving as senior vice president and head of clinical development and medical affairs in the specialty care business unit at pfizer we have strengthened our board with senior usbased pharma executives who bring tremendous value to the company” ms melincoff was named one of fierce biotech’s “top women in biotech ” as well as being named to the powerlist  of corporate venture capital in  and   she has a bs in biology a master’s of science in management and has obtained the designation of the certified licensing professional clp™ about kamadakamada ltd is focused on plasmaderived protein therapeutics for orphan indications and has a commercial product portfolio and a robust latestage product pipeline the company uses its proprietary platform technology and knowhow for the extraction and purification of proteins from human plasma to produce alpha antitrypsin aat in a highlypurified liquid form as well as other plasmaderived immune globulins  aat is a protein derived from human plasma with known and newlydiscovered therapeutic roles given its immunomodulatory antiinflammatory tissueprotective and antimicrobial properties the company’s flagship product is glassia® the first and only liquid readytouse intravenous plasmaderived aat product approved by the us food and drug administration kamada markets glassia® in the us through a strategic partnership with baxalta now part of shire plc and in other counties through local distributors  in addition to glassia® kamada has a product line of seven other pharmaceutical products administered by injection or infusion that are marketed through distributors in more than  countries including israel russia brazil india and other countries in latin america and asia kamada has five latestage plasmaderived protein products in development including an inhaled formulation of aat for the treatment of aat deficiency for which a maa was submitted to the ema after completing a pivotal phase  clinical trials in europe  kamada has also completed its phase  clinical trials in the us for the treatment of aat deficiency with inhaled aat in addition kamadas intravenous aat is in development for other indications such as type diabetes gvhd and prevention of lung transplant rejection kamada also leverages its expertise and presence in the plasmaderived protein therapeutics market by distributing more than  complementary products in israel that are manufactured by third parties cautionary note regarding forwardlooking statements this release includes forwardlooking statements within the meaning of section a of the us securities act of  as amended section e of the us securities exchange act of  as amended and the safe harbor provisions of the us private securities litigation reform act of   forwardlooking statements are statements that are not historical facts such as statements regarding assumptions and results related to financial results forecast commercial results timing and results of clinical trials and ema and us fda submissions and authorizations  forwardlooking statements are based on kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks uncertainties and assumptions  actual results and the timing of events could differ materially from those anticipated in these forwardlooking statements as a result of several factors including but not limited to unexpected results of clinical trials delays or denial in the us fda or the ema approval process additional competition in the aatd market or further regulatory delays  the forwardlooking statements made herein speak only as of the date of this announcement and kamada undertakes no obligation to update publicly such forwardlooking statements to reflect subsequent events or circumstances except as otherwise required by law contacts gil efron chief financial officer irkamadacom bob yedid lifesci advisors llc  boblifesciadvisorscom read at biospacecom related news kamada ltd kmda release company announces positive scientific advice response from the ema focused on alpha antitrypsin iv for treatment of acute graftversushost disease the story of a johnson  johnson jnj refugee scientist kamada ltd kmda reports financial results for the fourth quarter and fullyear  moving from big pharma to biotech—a conversation with achillion achns cso kamada ltd kmda to host fiscal year  financial results conference call on february   questions for bryan roberts of venture firm venrock kedrion and kamada ltd kmda announce fda acceptance of bla submission for human rabies immunoglobulin as a postexposure treatment teva teva ceo abruptly steps down excelgene celg boss named chairman of the board kamada ltd kmda announces plan for phase iiiii clinical trial with alpha antitrypsin iv for treatment of graftversushost disease  things to know about the biotech billionaire who wants to be trumps healthcare czar please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • kamada ltd   • biotechpharma  personnel • biotechpharma  personnel world